<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">53311</article-id><article-id pub-id-type="doi">10.7554/eLife.53311</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structural basis for pharmacological modulation of the TRPC6 channel</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-163503"><name><surname>Bai</surname><given-names>Yonghong</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4334-0916</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-164232"><name><surname>Yu</surname><given-names>Xinchao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-164233"><name><surname>Chen</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-164234"><name><surname>Horne</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-164235"><name><surname>White</surname><given-names>Ryan</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-164236"><name><surname>Wu</surname><given-names>Xiaosu</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-164237"><name><surname>Lee</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-164238"><name><surname>Gu</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-164239"><name><surname>Ghimire-Rijal</surname><given-names>Sudipa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" corresp="yes" id="author-164240"><name><surname>Lin</surname><given-names>Daniel C-H</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" corresp="yes" id="author-164241"><name><surname>Huang</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor4">*</xref><xref ref-type="fn" rid="conf12"/></contrib><aff id="aff1"><institution content-type="dept">Molecular Engineering</institution>, <institution>Amgen Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Molecular Engineering</institution>, <institution>Amgen Inc</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Protein Technologies</institution>, <institution>Amgen Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Medicinal Chemistry</institution>, <institution>Amgen Inc</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Cardiometabolic Disorders</institution>, <institution>Amgen Inc</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Discovery Technologies</institution>, <institution>Amgen Inc</institution>, <addr-line><named-content content-type="city">Thousand Oaks</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-25647"><name><surname>Csanády</surname><given-names>László</given-names></name><role>Reviewing editor</role><aff><institution>Semmelweis University</institution>, <country>Hungary</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>ybai80@gmail.com</email> (YB);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>xyu01@amgen.com</email> (XY);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>dclin@amgen.com</email> (DL);</corresp><corresp id="cor4"><label>*</label>For correspondence: <email>hxin@amgen.com</email> (XH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>09</day><month>03</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e53311</elocation-id><history><date date-type="received"><day>04</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>07</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Bai et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Bai et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-53311-v1.pdf"/><abstract><p>Transient receptor potential canonical (TRPC) proteins form nonselective cation channels that play physiological roles in a wide variety of cells. Despite growing evidence supporting the therapeutic potential of TRPC6 inhibition in treating pathological cardiac and renal conditions, mechanistic understanding of TRPC6 function and modulation remains obscure. Here we report cryo-EM structures of TRPC6 in both antagonist-bound and agonist-bound states. The structures reveal two novel recognition sites for the small-molecule modulators corroborated by mutagenesis data. The antagonist binds to a cytoplasm-facing pocket formed by S1-S4 and the TRP helix, whereas the agonist wedges at the subunit interface between S6 and the pore helix. Conformational changes upon ligand binding illuminate a mechanistic rationale for understanding TRPC6 modulation. Furthermore, structural and mutagenesis analyses suggest several disease-related mutations enhance channel activity by disrupting interfacial interactions. Our results provide principles of drug action that may facilitate future design of small molecules to ameliorate TRPC6-mediated diseases.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Yonghong Bai, At the time of the study YB was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Xinchao Yu, XY is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf4"><p>Hao Chen, At the time of the study HC was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf5"><p>Daniel Horne, At the time of the study DH was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf6"><p>Ryan White, At the time of the study RW was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf7"><p>Xiaosu Wu, XW is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf8"><p>Paul Lee, At the time of the study PL was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf9"><p>Yan Gu, At the time of the study YG was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf10"><p>Sudipa Ghimire-Rijal, SGR is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf11"><p>Daniel C-H Lin, DCHL is affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf12"><p>Xin Huang, At the time of the study XH was affiliated with Amgen Research, Amgen Inc. and has no financial interests to declare.  The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The low pass filtered and amplitude modified 3D cryo-EM density maps for TRPC6 in complex with antagonist AM-1473 (accession code: EMD-20954) and agonist AM-0883 (accession code: EMD-20953) have been deposited in the electron microscopy data bank. Atomic coordinates for TRPC6 in complex with antagonist AM-1473 (accession code: 6UZA) and agonist AM-0883  (accession code: 6UZ8) have been deposited in the protein data bank.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Bai Y</collab><collab>Yu X</collab><collab>Huang X</collab><collab>Chen H</collab></person-group><year iso-8601-date="2019">2019</year><source>Cryo-EM structure of human TRPC6 in complex with antagonist AM-1473</source><ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/structure/6UZA">http://www.rcsb.org/structure/6UZA</ext-link><comment>RCSB Protein Data Bank, 6UZA</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Bai Y</collab><collab>Yu X</collab><collab>Huang X</collab><collab>Chen H</collab></person-group><year iso-8601-date="2019">2019</year><source>Cryo-EM structure of human TRPC6 in complex with antagonist AM-1473</source><ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20954">http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20954</ext-link><comment>Electron Microscopy Data Bank, EMD-20954</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Bai Y</collab><collab>Yu X</collab><collab>Huang X</collab><collab>Chen H</collab></person-group><year iso-8601-date="2019">2019</year><source>Cryo-EM structure of human TRPC6 in complex with agonist AM-0833</source><ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/structure/6UZ8">http://www.rcsb.org/structure/6UZ8</ext-link><comment>RCSB Protein Data Bank, 6UZ8</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Bai Y</collab><collab>Yu X</collab><collab>Huang X</collab><collab>Chen H</collab></person-group><year iso-8601-date="2019">2019</year><source>Cryo-EM structure of human TRPC6 in complex with agonist AM-0833</source><ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20953">http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-20953</ext-link><comment>Electron Microscopy Data Bank, EMD-20953</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-53311-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>